Premium
The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine—A case report
Author(s) -
Kuzin Maxim,
Scharrer Isabel,
Nolan Daniele,
Baumgartner Markus,
Paulzen Michael,
Schoretsanitis Georgios,
Xepapadakos Franziskos
Publication year - 2020
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.13428
Subject(s) - cyp2d6 , venlafaxine , duloxetine , pharmacogenetics , pharmacokinetics , pharmacology , cyp1a2 , duloxetine hydrochloride , cyp2c19 , genotype , medicine , biology , genetics , cytochrome p450 , gene , antidepressant , metabolism , alternative medicine , pathology , hippocampus
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom